DE2136763A1 - Neue Benzamide Stickstoff enthaltender Heterocyclen und Verfahren zur Herstellung derselben - Google Patents
Neue Benzamide Stickstoff enthaltender Heterocyclen und Verfahren zur Herstellung derselbenInfo
- Publication number
- DE2136763A1 DE2136763A1 DE19712136763 DE2136763A DE2136763A1 DE 2136763 A1 DE2136763 A1 DE 2136763A1 DE 19712136763 DE19712136763 DE 19712136763 DE 2136763 A DE2136763 A DE 2136763A DE 2136763 A1 DE2136763 A1 DE 2136763A1
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- lower alkyl
- aminated
- compound according
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 8
- 229940054066 benzamide antipsychotics Drugs 0.000 title description 2
- 150000003936 benzamides Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- -1 nitro, amino Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- XVCFWFMLNSQUKQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-2-ylmethanamine Chemical compound C1CN2C(CN)CC1CC2 XVCFWFMLNSQUKQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001408 amides Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- XYMVZPOXZCDCNP-UHFFFAOYSA-N sulfamoyl cyanide Chemical compound NS(=O)(=O)C#N XYMVZPOXZCDCNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical compound COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SQAILWDRVDGLGY-UHFFFAOYSA-N 2-methoxy-5-sulfamoylbenzoic acid Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1C(O)=O SQAILWDRVDGLGY-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB35787/70A GB1293446A (en) | 1970-07-23 | 1970-07-23 | Quinuclidine derivatives, the preparation thereof and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2136763A1 true DE2136763A1 (de) | 1972-01-27 |
Family
ID=10381553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712136763 Pending DE2136763A1 (de) | 1970-07-23 | 1971-07-22 | Neue Benzamide Stickstoff enthaltender Heterocyclen und Verfahren zur Herstellung derselben |
Country Status (11)
| Country | Link |
|---|---|
| AT (1) | AT311375B (enExample) |
| AU (1) | AU464500B2 (enExample) |
| BE (1) | BE769615A (enExample) |
| CA (1) | CA946402A (enExample) |
| CH (1) | CH535770A (enExample) |
| DE (1) | DE2136763A1 (enExample) |
| FR (1) | FR2100940B1 (enExample) |
| GB (1) | GB1293446A (enExample) |
| IL (1) | IL37340A (enExample) |
| NL (1) | NL7110187A (enExample) |
| ZA (1) | ZA714800B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2183565A1 (enExample) * | 1972-05-10 | 1973-12-21 | Cerm Cent Europ Rech Mauvernay |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2514006A1 (fr) * | 1981-10-05 | 1983-04-08 | Nativelle Sa Ets | Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique |
| FI74707C (fi) * | 1982-06-29 | 1988-03-10 | Sandoz Ag | Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror. |
| WO1985001048A1 (en) * | 1983-08-26 | 1985-03-14 | Sandoz Ag | Aromatic esters or amides of carboxylic acid and sulfonic acid |
| US4593034A (en) * | 1984-04-06 | 1986-06-03 | A. H. Robins Company, Inc. | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides |
| US4605652A (en) * | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
| GB8525844D0 (en) * | 1985-10-19 | 1985-11-20 | Beecham Group Plc | Compounds |
| US5446050A (en) * | 1989-11-17 | 1995-08-29 | Pfizer Inc. | Azabicyclo amides and esters as 5-HT3 receptor antagonists |
| WO1991007402A1 (en) * | 1989-11-17 | 1991-05-30 | Pfizer Inc. | Azabicyclo amides and esters as 5-ht3 receptor antagonists |
-
1970
- 1970-07-23 GB GB35787/70A patent/GB1293446A/en not_active Expired
-
1971
- 1971-07-07 BE BE769615A patent/BE769615A/xx unknown
- 1971-07-08 FR FR7124956A patent/FR2100940B1/fr not_active Expired
- 1971-07-08 CH CH1017771A patent/CH535770A/fr not_active IP Right Cessation
- 1971-07-19 IL IL37340A patent/IL37340A/xx unknown
- 1971-07-20 ZA ZA714800A patent/ZA714800B/xx unknown
- 1971-07-21 AT AT634471A patent/AT311375B/de active
- 1971-07-21 CA CA118,807*7A patent/CA946402A/en not_active Expired
- 1971-07-22 AU AU31567/71A patent/AU464500B2/en not_active Expired
- 1971-07-22 DE DE19712136763 patent/DE2136763A1/de active Pending
- 1971-07-23 NL NL7110187A patent/NL7110187A/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2183565A1 (enExample) * | 1972-05-10 | 1973-12-21 | Cerm Cent Europ Rech Mauvernay |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1293446A (en) | 1972-10-18 |
| IL37340A0 (en) | 1971-12-29 |
| NL7110187A (enExample) | 1972-01-25 |
| AT311375B (de) | 1973-11-12 |
| CH535770A (fr) | 1973-04-15 |
| ZA714800B (en) | 1972-04-26 |
| CA946402A (en) | 1974-04-30 |
| AU3156771A (en) | 1973-01-25 |
| IL37340A (en) | 1975-12-31 |
| BE769615A (fr) | 1971-11-16 |
| AU464500B2 (en) | 1975-08-28 |
| FR2100940B1 (enExample) | 1975-06-06 |
| FR2100940A1 (enExample) | 1972-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH620200A5 (enExample) | ||
| DE2012138B2 (de) | N-eckige klammer auf 4-(beta-pyrazin- 2-carboxyamido-aethyl)-benzolsulphonyl eckige klammer zu -n' - cycloalkylharnstoffe und diese enthaltende pharmazeutische praeparate | |
| DE2136763A1 (de) | Neue Benzamide Stickstoff enthaltender Heterocyclen und Verfahren zur Herstellung derselben | |
| DE2446758A1 (de) | Neue 2,6-disubstituierte 2-phenylimino- imidazolidine, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung | |
| CH449632A (de) | Verfahren zur Herstellung von cyclischen Diazacycloalkanverbindungen | |
| DE2144077C3 (de) | Neue Hydroxyäthylaminoalkylpiperazine und Verfahren zu deren Herstellung | |
| DE2143590A1 (de) | 1-Nitrosopyrrolidine und Verfahren zu deren Herstellung | |
| CH392498A (de) | Verfahren zur Herstellung von neuen Benzolsulfonyl-cyclohexyl-harnstoffen | |
| DE1518311B1 (de) | N-(2-Diaethylaminoaethyl)-2-methoxy-3,4- bzw. 4,5-methylendioxybenzamid und deren pharmakologisch nicht giftige Saeureadditionssalze | |
| DE1645901C3 (de) | gamma-(4-Alkylp!peridino)-p-fluorbutyrophenone und Verfahren zu ihrer Herstellung | |
| DE2748794C2 (de) | Malonylharnstoffkomplexe, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| AT218021B (de) | Verfahren zur Herstellung von neuen Piperazinverbindungen | |
| AT254182B (de) | Verfahren zur Herstellung von neuen substituierten Benzamiden und deren Säureadditionssalzen | |
| DE1493828A1 (de) | Verfahren zur Herstellung von substituierten Benzamiden | |
| DE1131679B (de) | Verfahren zur Herstellung von Phenthiazinverbindungen | |
| AT353281B (de) | Verfahren zur herstellung von neuen 4-(beta- -ureidoaethyl)-benzolsulfonylharnstoffen und deren salzen | |
| AT356665B (de) | Verfahren zum herstellen neuer chinuclidin- derivate, ihren stereoisomeren, optischen isomeren und salzen | |
| CH459978A (de) | Verfahren zur Herstellung von Benzolsulfonylharnstoffen | |
| DE1518311C (de) | N (2 Diathylaminoathyl) 2 methoxy 3,4 bzw 4,5 methylendioxybenzamid und deren pharmakologisch nicht giftige Saureadditions salze | |
| AT265259B (de) | Verfahren zur Herstellung von neuen rechtsdrehenden und linksdrehenden Formen von 1-(β-Hydroxy- oder -Halogen-äthyl)-diphenylmethyl-piperidinen und ihren Salzen | |
| CH374984A (de) | Verfahren zur Herstellung von Benzolsulfonylharnstoffen | |
| AT226728B (de) | Verfahren zur Herstellung von neuen Benzolsulfonyl-cyclohexyl-harnstoffen | |
| AT228798B (de) | Verfahren zur Herstellung von neuen Benzolsulfonylharnstoffen | |
| AT219052B (de) | Verfahren zur Herstellung von neuen Sulfonylharnstoffen | |
| DE2730312A1 (de) | (2-azabicyclo eckige klammer auf 2.2.2 eckige klammer zu octan-2-yl) diphenyl-alkanone, verfahren zu deren herstellung sowie dieselben enthaltende pharmazeutische praeparate |